miRNA-mediated TUSC3 deficiency enhances UPR and ERAD to promote metastatic potential of NSCLC.
AffiliationComprehensive Cancer Center, The Ohio State University, Columbus, OH, 43210, USA
MetadataShow full item record
AbstractNon-small cell lung carcinoma (NSCLC) is leading cause of cancer-related deaths in the world. The Tumor Suppressor Candidate 3 (TUSC3) at chromosome 8p22 known to be frequently deleted in cancer is often found to be deleted in advanced stage of solid tumors. However, the role of TUSC3 still remains controversial in lung cancer and context-dependent in several cancers. Here we propose that miR-224/-520c-dependent TUSC3 deficiency enhances the metastatic potential of NSCLC through the alteration of three unfolded protein response pathways and HRD1-dependent ERAD. ATF6?-dependent UPR is enhanced whereas the affinity of HRD1 to its substrates, PERK, IRE1? and p53 is weakened. Consequently, the alteration of UPRs and the suppressed p53-NM23H1/2 pathway by TUSC3 deficiency is ultimately responsible for enhancing metastatic potential of lung cancer. These findings provide mechanistic insight of unrecognized roles of TUSC3 in cancer progression and the oncogenic role of HRD1-dependent ERAD in cancer metastasis.
CitationJeon YJ, Kim T, Park D, Nuovo GJ, Rhee S, Joshi P, et al. miRNA-mediated TUSC3 deficiency enhances UPR and ERAD to promote metastatic potential of NSCLC. Nat Commun. 2018 Nov 30;9(1):5110.
- Oncogenic function of TUSC3 in non-small cell lung cancer is associated with Hedgehog signalling pathway.
- Authors: Gu Y, Pei X, Ren Y, Cai K, Guo K, Chen J, Qin W, Lin M, Wang Q, Tang N, Cheng Z, Ding Y, Lin J
- Issue date: 2017 Jul
- TUSC3 accelerates cancer growth and induces epithelial-mesenchymal transition by upregulating claudin-1 in non-small-cell lung cancer cells.
- Authors: Feng S, Zhai J, Lu D, Lin J, Dong X, Liu X, Wu H, Roden AC, Brandi G, Tavolari S, Bille A, Cai K
- Issue date: 2018 Dec 15
- IRE1α is an endogenous substrate of endoplasmic-reticulum-associated degradation.
- Authors: Sun S, Shi G, Sha H, Ji Y, Han X, Shu X, Ma H, Inoue T, Gao B, Kim H, Bu P, Guber RD, Shen X, Lee AH, Iwawaki T, Paton AW, Paton JC, Fang D, Tsai B, Yates JR 3rd, Wu H, Kersten S, Long Q, Duhamel GE, Simpson KW, Qi L
- Issue date: 2015 Dec
- miR-873-5p inhibits the progression of colon cancer via repression of tumor suppressor candidate 3/AKT signaling.
- Authors: Zhu Y, Zhang X, Qi M, Zhang Y, Ding F
- Issue date: 2019 Dec
- Tumor-suppressive p53 Signaling Empowers Metastatic Inhibitor KLF17-dependent Transcription to Overcome Tumorigenesis in Non-small Cell Lung Cancer.
- Authors: Ali A, Bhatti MZ, Shah AS, Duong HQ, Alkreathy HM, Mohammad SF, Khan RA, Ahmad A
- Issue date: 2015 Aug 28